Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T Program at the 59th American Society of Hematology Annual Meeting

HOUSTON, Nov. 01, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that four abstracts, including an oral presentation on the Company’s lead product candidate BPX-501, were accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting.

In the oral presentation, Pietro Merli of Ospedale Pediatrico Bambino Gesù in Rome, Italy will review data from the ongoing EU BP-004 study, highlighting rapid immune recovery in pediatric patients with blood cancers, immune deficiencies and other non-malignant disorders receiving treatment with BPX-501 following an alpha/beta-depleted haploidentical hematopoietic stem cell transplant. The Company will also present data highlighting preclinical results of its controllable CAR-T technology in three poster presentations, including a study evaluating Bellicum’s dual-switch CAR-T cells targeting CD123. ASH 2017 is being held in Atlanta, Georgia on December 9-12.

ASH Presentations on Bellicum Programs

BPX-501:

Oral Presentation: “Donor T Cells Genetically Modified with a Novel Suicide Gene (Inducible Caspase 9, iC9) Expand and Persist Over Time After Post-Allograft Infusion in Patients Given αβ T-Cell and B-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (αβ Haplo-HSCT) Contributing to Accelerate Immune Recovery”
Abstract Number: 211
Session Name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Prevention 
Session Date: Saturday, December 9, 2017 
Session Time: 2:00 p.m. - 3:30 p.m. EST
Presentation Time: 2:00 p.m. EST

Controllable CAR-T Technology:

Poster Presentation: “Dual-Switch CAR-T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123⁺ Cancer”
Abstract Number: 3184
Session Name: 703. Adoptive Immunotherapy: Poster II 
Date: Sunday, December 10, 2017 
Presentation Time: 6:00 p.m. - 8:00 p.m. EST 

Poster Presentation: “Inducible MyD88/CD40 (iMC) Costimulation Enhances Polyclonal Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte (EBV-CTL) Proliferation and Anti-Tumor Activity”
Abstract Number: 3337
Session Name: 801. Gene Therapy and Transfer: Poster II 
Date: Sunday, December 10, 2017 
Presentation Time: 6:00 p.m. - 8:00 p.m. EST

Poster Presentation: “MyD88/CD40 Enhanced CD19-Specific CAR-T Cells Maintain Therapeutic Efficacy Following Resolution of Cytokine-Related Toxicity Using Inducible Caspase-9”
Abstract Number: 4615
Session Name: 801. Gene Therapy and Transfer: Poster III 
Date: Monday, December 11, 2017 
Presentation Time: 6:00 p.m. - 8:00 p.m. EST

About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including allogeneic hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals

Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
[email protected] 

Media:
BMC Communications
Brad Miles
646-513-3125
[email protected]